Ayana is a pharmaceutical company focused on development of Liposomal Therapeutics for the treatment of cancer
Founded in 2012 by Prof. Chezy Barenholz (co-inventor of Doxil® - Doxorubicin-HCl Liposomal Injection)
Lead product LC101 (Doxorubicin-HCl Liposomal Injection) approved by FDA for treatment of Ovarian Cancer, Multiple Myeloma and AIDS-related Kaposi’s Sarcoma
Secured FDA accredited, cGMP manufacturing facility to support commercial launch
Strategic agreement with tier 1 pharma company for commercialization of LC101 in the U.S. market
Overall $500m WW market opportunity with very few competitors due to high entry barriers (i.e. complex nonotechnology drug)
Accomplished company leadership
